期刊文献+

胃癌同时合并腹水的临床病理特点及D2根治手术对预后的影响 被引量:2

Correlation analysis of the ascites in gastric cancer and clinicopathologic meaning and the impact of the standard D2 resection on the prognosis
下载PDF
导出
摘要 目的分析182例胃癌同时合并腹水患者的临床病理资料,探讨D2根治术对预后的影响。方法回顾性分析我科1994年9月-2009年9月182例胃癌同时合并腹水及胃癌无腹水1 124例的临床病理资料和随访状况。结果胃癌同时合并腹水与卵巢瘤、盆底结节、浸润深度、转移淋巴结、腹膜种植、肝转移、BORRMANN分型、脏器侵犯、CEA〉5μg/L有关,有显著统计学意义(P〈0.01),而性别、年龄、WHO组织学分型、分化程度与胃癌同时合并腹水无关(P〉0.05),Logistic回归分析发现盆底结节(P=0.005)、腹膜种植(P=0.000)及脏器侵犯(P=0.000)与胃癌同时合并腹水关系最密切。胃癌同时合并腹水行D2根治术后1、3、5年累积生存率达45%、34%、26%,未行D2根治术1、3、5年的累积生存率只有17%、5%、1%(P=0.000、0.000、0.000)。结论胃癌同时合并腹水是胃癌晚期事件,胃癌同时合并腹水预后比无腹水的患者差;胃癌合并腹水推荐行标准的D2根治术,可改善胃癌同时合并腹水患者的远近期生存率。 Objective To analyse the related clinicopathologic factors in 182 gastric cancer patients with ascites and explore the impact of the standard D2 resection on the prognosis.Methods The clinicopathologic and follow-up data of 182 gastric cancer patients with ascites and 1 124 with no ascites who were operated in our hospital from Sep 1994 to Sep 2009 were reviewed and analyzed retrospectively.Results Pelvic nodular mass,ovary tumor,depth of infiltration,lymph node metastasis,peritoneal implantation metastasis,hepatic metastasis,BORRMANN typing,invasion of neighboring organs and CEA〉5μg/ L were correlated with malignant ascites(P〈0.01),while sex,age,WHO histological typing and differentiation were incorrelate with malignant ascites(P〉0.05).Logistic regression analysis showed that pelvic nodular mass,peritoneal implantation metastasis and invasion of neighboring organs were independent risk factors for gastric cancer with ascites respectively(P=0.005,0.000,0.000).Gastric cancer patients with ascites who took the D2 radical resection had a higher 1,3,5 years survival rate which reached 45%,34%,26%,and the other only reached 17%,5%,1%(P=0.000,0.000,0.000).Conclusion Ascites in gastric cancer patients is an end stage event and the prognosis is worse than those who have no ascites.We recommend the standard D2 resection in patients with ascites and could improve the survival rate.
出处 《中国现代医药杂志》 2012年第8期1-6,共6页 Modern Medicine Journal of China
基金 广东省自然科学基金资助(编号:9151008901000119) 黄埔区科技计划项目资助(编号:2009031)
关键词 胃癌 腹水 临床病理 D2根治术 预后 Gastric cancer Ascites Clinicopathologic factors The standard D2 resection Prognosis
  • 相关文献

参考文献2

二级参考文献29

  • 1朱金水,徐家裕,王冠庭,瞿祖康,王易,周丽丽,徐文玉,马宝骊.细胞因子水平与晚期胃癌患者治疗及预后相关研究[J].中华微生物学和免疫学杂志,1995,15(1):49-52. 被引量:41
  • 2[1]Rowinsky EK,Donehower RC.Paclitaxel (taxol) N Engl J Med 1995; 332:1004-1014
  • 3[2]Chang YF,Li LL,Wu CW,Liu TY,Lui WY,P'eng FK,Chi CW.Paclitaxel-induced apoptosis in human gastric carcinoma cell lines.Cancer 1996; 77:14-18
  • 4[3]Kim YH,Shin SW,Kim BS,Kim JH,Kim JG,Mok YJ,Kim CS,Rhyu HS,Hyun JH,Kim JS.Paclitaxel,5-fluorouracil,and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma.Cancer 1999; 85:295-301
  • 5[4]Murad AM,Petroianu A,Guimaraes RC,Aragao BC,Cabral LO,Scalabrini-Neto AO.Phase Ⅱ trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer:a novel,safe,and effective regimen.Am J Clin Oncol 1999; 22:580-586
  • 6[5]Lokich JJ,Sonneborn H,Anderson NR,Bern MM,Coco FV,Dow E,Oliynyk P.Combined paclitaxel,cisplatin,and etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas.Cancer 1999; 85:2347-2351
  • 7[6]Kollmannsberger C,Quietzsch D,Haag C,Lingenfelser T,Schroeder M,Hartmann JT,Baronius W,Hempel V,Clemens M,Kanz L,Bokemeyer C.A phase Ⅱ study of paclitaxel,weekly,24-hour continous infusion 5-fluorouracil,folinic acid and cisplatin in patients with advanced gastric cancer.Br J Cancer 2000; 83:458-462
  • 8[7]Garcia AA,Leichman CG,Lenz HJ,Baranda J,Lujan R,Casagrande Y,Leichman L.Phase Ⅱ trial of outpatient schedule of paclitaxel in patients with previously untreated metastatic,measurable adenocarcinoma of the stomach.Jpn J Clin Oncol 2001; 31:275-278
  • 9[8]Yamada Y,Shirao K,Ohtsu A,Boku N,Hyodo I,Saitoh H,Miyata Y,Taguchi T.Phase Ⅱ trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions.Ann Oncol 2001; 12:1133-1137
  • 10[9]Wiernik PH,Schwartz EL,Einzig A,Strauman JJ,Lipton RB,Dutcher JP.Phase Ⅰ trial of taxol given as a 24-hour infusion every 21 days:responses observed in metastatic melanoma.J Clin Oncol 1987; 5:1232-1239

共引文献21

同被引文献12

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部